<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01447095</url>
  </required_header>
  <id_info>
    <org_study_id>2011-002798-50</org_study_id>
    <nct_id>NCT01447095</nct_id>
  </id_info>
  <brief_title>Effects of Prostacyclin Infusion on Cerebral Vessels and Metabolism in Patients With Subarachnoid Haemorrhage</brief_title>
  <official_title>Effect of Prostacyclin Infusion on Cerebral Vessels, Cerebral Bloodflow and Cerebral Metabolism in Patients With Subarachnoid Haemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rune Rasmussen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether prostacyclin is effective in prevention of
      cerebral vasospasm in patients with subarachnoidal hemorrhage (SAH).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic vasospasm measured by CT perfusion</measure>
    <time_frame>Day 8 (+/- 1 day) after aneurysm treatment</time_frame>
    <description>Changes in regional cerebral blood flow from baseline in the arterial territories of the anterior cerebral artery, medial cerebral artery and the posterior cerebral artery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebral metabolism measured by microdialysis</measure>
    <time_frame>every 2. hour day 3-10 after aneurysm treatment</time_frame>
    <description>Cerebral metabolism measured by microdialysis. Lactate, pyruvate, glucose, glutamate and glycerol are measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow outcome scale (GOS) at 3 months</measure>
    <time_frame>3 months efter SAH</time_frame>
    <description>Glasgow outcome scale (GOS) at 3 months obtained by telephone interview.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical vasospasm</measure>
    <time_frame>day 5-10 after SAH</time_frame>
    <description>Clinical vasospasm defined as delayed neurological deficits (DIND).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain tissue oxygen (PtiO2)</measure>
    <time_frame>continuous measurement day 3-10 after SAH</time_frame>
    <description>Brain tissue oxygen (PtiO2) measured by Licox catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial pressure (MAP)</measure>
    <time_frame>Continuous day 1-10 after SAH</time_frame>
    <description>Mean arterial pressure (MAP) measured by arterial catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic vasospasm measured by CT angiography</measure>
    <time_frame>Measured day 8 +/- 1 day</time_frame>
    <description>Qualitative assessment (none, mild/moderate, severe) of vasospasm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of brain damage biomarker</measure>
    <time_frame>daily day 4-11 after SAH</time_frame>
    <description>Serum levels of S100b in peripheral blood</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Neuropeptide Y</measure>
    <time_frame>May 2014</time_frame>
    <description>Neuropeptide Y will be measured in all patients Day 2-11. The concentration will be related to CBF, angiographic vasospasm and clinical outcome for all patients. The results will be reported in a separate puplication.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Low dose prostacyclin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose prostacyclin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prostacyclin 1 ng/kg/min</intervention_name>
    <description>Continuous i.v. infusion of epoprostenol 1 ng/kg/min day 5-10 after SAH</description>
    <arm_group_label>Low dose prostacyclin</arm_group_label>
    <other_name>Flolan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prostacyclin 2 ng/kg/min</intervention_name>
    <description>Continuous i.v. infusion of epoprostenol 2 ng/kg/min day 5-10 after SAH</description>
    <arm_group_label>High dose prostacyclin</arm_group_label>
    <other_name>Flolan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Continuous i.v. infusion with placebo day 5-10 after SAH</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SAH verified by CT

          -  Aneurysm identified and treated

          -  Fisher grade 3 + 4

          -  WFNS grade 1-4 (World Federation of Neurosurgical Societies )

        Exclusion Criteria:

          -  Pregnancy/lactation

          -  Heard failure

          -  Kidney failure

          -  Liver failure

          -  Hemorrhagic diathesis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rune Rasmussen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet, dep. of neurosurgery</name>
      <address>
        <city>Copenhagen</city>
        <zip>2200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2011</study_first_submitted>
  <study_first_submitted_qc>October 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2011</study_first_posted>
  <last_update_submitted>July 18, 2014</last_update_submitted>
  <last_update_submitted_qc>July 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Rune Rasmussen</investigator_full_name>
    <investigator_title>MD, Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Subarachnoid hemorrhage</keyword>
  <keyword>vasospasm</keyword>
  <keyword>prostacyclin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoprostenol</mesh_term>
    <mesh_term>Tezosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

